| Literature DB >> 35910033 |
László Mózsik1, Riccardo Iacovelli1, Roel A L Bovenberg2,3, Arnold J M Driessen1.
Abstract
Filamentous fungi are highly productive cell factories, many of which are industrial producers of enzymes, organic acids, and secondary metabolites. The increasing number of sequenced fungal genomes revealed a vast and unexplored biosynthetic potential in the form of transcriptionally silent secondary metabolite biosynthetic gene clusters (BGCs). Various strategies have been carried out to explore and mine this untapped source of bioactive molecules, and with the advent of synthetic biology, novel applications, and tools have been developed for filamentous fungi. Here we summarize approaches aiming for the expression of endogenous or exogenous natural product BGCs, including synthetic transcription factors, assembly of artificial transcription units, gene cluster refactoring, fungal shuttle vectors, and platform strains.Entities:
Keywords: biosynthetic gene cluster; fungal platform strains; secondary metabilites; synthetic biology; synthetic transcriptional regulators
Year: 2022 PMID: 35910033 PMCID: PMC9335490 DOI: 10.3389/fbioe.2022.901037
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1Schematic representation of a fungal biosynthetic gene cluster (BGCs) (A) and structurally different, representative members of nonribosomal peptides synthetase (NRPS), and polyketides synthase (PKS), terpenes synthase produced secondary metabolites and indole alkaloids from fungi (B).
Examples of fungal expression platforms for the production of natural products and the characterization of biosynthetic gene clusters.
| Species | Platform strains | Genotype | Examples of NP | References |
|---|---|---|---|---|
|
| A1145 | pyrG89; | Flavunoidine |
|
| A1145 ΔSTΔEM | A1145 Δ | Myceliothermophin |
| |
| LO4389 | A1145 Δ | Zaragozic acid A precursor |
| |
| LO8030 | A1145 Δ | Trihazone A-F |
| |
| YM87 & YM137 | LO4389 AN1029:: | Asperfuranone |
| |
| A1145 Δstc-BGC, Δeas-BGC | Aspercryptin |
| ||
| A1145 ΔstcA-stcW | Felinone A |
| ||
| Citreoviridin |
| |||
| Mutilin |
| |||
| Pleuromutilin |
| |||
|
| NSAR1 |
| Strobilurin |
|
| NSARΔK | NSAR1 Δ | Paxilline |
| |
| NSPlD1 |
| Erinacine Q |
| |
| Pretenellin A |
| |||
| Kojic acid |
| |||
|
| AB1.13 |
| Enniatin |
|
| Beauvaricin |
| |||
| Bassianolide |
| |||
|
| ΔakuB | SBUG844 Δ | Isoflavipucine |
|
| HZ03 | Δ | Dihydroisoflavipucine |
| |
| Monacolin J |
| |||
|
| 4xKO | ∆ | Penicillin |
|
| Decumbenone A-C |
| |||
|
| ΔpyrG | QM6a Δ | Sorbicillinoids |
|
Transcriptional activation tools and methods for fungal biosynthetic gene clusters.
| Transcriptional activation method | Benefits | Drawbacks |
|---|---|---|
| Overexpression of BGC core gene | • Reliable transcriptional activation of the targeted gene | • Although transcription is activated, product formation is not ensured |
| • Limited genomic modulation needed | • Does not activate the complete BGC | |
| Modulation of BGC-specific TF | • Limited genomic modulation needed | • Often no cluster-specific TFs are present in a BGC |
| • Overexpression of positive regulator can upregulate entire BGCs | • Overexpression of such TF does not guarantee transcriptional activation of the entire BGC | |
| • Other co-activators, mediators or inducers might be needed for activation | ||
| Modulation of global regulators | • Limited genomic modulation needed | • Regulator needs to be identified |
| • Multiple BGCs are affected, resulting in higher chances for compound discovery | • Global regulator targets are often unknown | |
| • Modulation can be lethal | ||
| • Difficult to assign newly produced compounds to specific BGCs | ||
| Epigenome modulation | • Feeding of chemical modulators is easy to carry out | • Histone modifying enzymes have to be identified and engineered |
| • Multiple BGCs are affected, resulting in higher chances for compound discovery | • Modulation can be lethal | |
| • Difficult to assign newly produced compounds to specific BGCs | ||
| BGC refactoring | • Native regulatory system is bypassed | • Requires extensive DNA cloning and/or synthesis efforts |
| • Episomal delivery of BGCs can lift the burden of epigenetic repression | • Limited number of established promoters | |
| • Transcription relies solely on established promoters | ||
| • Fungal SM deficient strains are available | ||
| Heterologous expression in non-fungal host | • Established heterologous systems and regulation tools are broadly available | • Potential problems with codon usage, available precursors, cellular trafficking, RNA splicing and post-translational modifications |
| STF-based BGC regulation | • Native regulatory system is eliminated or bypassed | • Extensive DNA cloning and/or DNA synthesis effort required |
| • Transcription relies on an orthogonal regulatory system | • Genome editing or BGC refactoring is required | |
| • Modular features and scalable transcriptional regulation possible | • Validation (specificity, activity) of new STFs is necessary | |
| CRISPR-based BGC regulation | • Genome editing-free transcriptional activation or repression | • Extensive DNA cloning and/or DNA synthesis effort required |
| • Rapid library construction | • Genome editing or BGC refactoring is required | |
| • Various regulatory domains are available for transcriptional activation, repression or epigenetic modulation | • No established rules available for creating STF fusions | |
| • Preceding validation required (activity, specificity) |
FIGURE 2Strategies for transcriptional activation for fungal biosynthetic gene clusters. Dashed arrows indicate native, solid arrows indicate engineered (strong or inducible) promoters.